OGN News & Events

Reports Q1 revenue $1.46B, consensus $1.49B.

In light of the pending merger, Organon will not be providing financial guidance or hosting quarterly earnings calls.

Organon canceled its first quarter 2026 earnings conference call previously scheduled for May 7, 2026. The cancellation is the result of the company's April 26, 2026 announcement that it has entered into an agreement under which Sun Pharmaceutical Industries Limited will acquire Organon. Organon will issue its first quarter financial results on April 30, 2026 in a press release, as well as in a subsequent Form 10-Q that it will file with the U.S. Securities and Exchange Commission.

Shanghai Henlius Biotech and Organon announced the European Commission has granted marketing authorization for Poherdy 420 mg/14 mL injection for intravenous use. In 2022, Henlius entered into a license and supply agreement with Organon, granting Organon the exclusive commercialization rights to several biosimilars, including Poherdy. The agreement covers exclusive global commercialization rights except for China.